The cell-therapy company TiGenix NV has raised gross proceeds of $35.65 million in an initial public offering of its shares on the Nasdaq exchange in the US in order to support the clinical development of its allogeneic product portfolio. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
